You are here
Reshma Kewalramani, M.D.
Reshma Kewalramani, M.D., FASN, joined Vertex in 2017 as Senior Vice President, Late Development. In this role, Dr. Kewalramani leads the Cystic Fibrosis and General Medicine Clinical Development therapeutic areas, Clinical Development Execution, Medical Writing and Medical Affairs.
Prior to Vertex, Dr. Kewalramani spent more than 12 years at Amgen where she held a variety of roles across Research and Development, including as Vice President Global Clinical Development, Nephrology & Metabolic Therapeutic Area and Vice President, US Medical Organization, a group she established and grew to assume responsibility for the full portfolio of molecules across six therapeutic areas.
Dr. Kewalramani is the industry representative to the FDA’s Endocrine and Metabolic Drug Advisory Committee and is on the Board of Directors of the Kidney Health Initiative. She completed her internship and residency in Internal Medicine at the Massachusetts General Hospital and her fellowship in Nephrology at the Massachusetts General Hospital and Brigham and Women’s Hospital combined program. Dr. Kewalramani is also an alumnus of the Harvard Business School.